Castle BiosciencesCSTL
About: Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.
Employees: 703
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
326% more call options, than puts
Call options by funds: $12.1M | Put options by funds: $2.83M
300% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 4 (+3) [Q2]
33% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 24
15% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 48
5% more funds holding
Funds holding: 150 [Q1] → 158 (+8) [Q2]
5% less capital invested
Capital invested by funds: $581M [Q1] → $553M (-$27.6M) [Q2]
3.39% less ownership
Funds ownership: 95.49% [Q1] → 92.1% (-3.39%) [Q2]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
Scotiabank Sung Ji Nam 65% 1-year accuracy 13 / 20 met price target | 32%upside $44 | Sector Outperform Maintained | 6 Nov 2024 |
Lake Street Thomas Flaten 50% 1-year accuracy 4 / 8 met price target | 20%upside $40 | Buy Maintained | 5 Nov 2024 |
Keybanc Paul Knight 50% 1-year accuracy 4 / 8 met price target | 8%upside $36 | Overweight Maintained | 5 Nov 2024 |
Baird Catherine Ramsey 88% 1-year accuracy 7 / 8 met price target | 17%upside $39 | Outperform Maintained | 5 Nov 2024 |
Canaccord Genuity Kyle Mikson 59% 1-year accuracy 10 / 17 met price target | 26%upside $42 | Buy Maintained | 29 Oct 2024 |
Financial journalist opinion
Based on 19 articles about CSTL published over the past 30 days